Skip to main content

Table 2 Adjusted hazard ratios/odds ratio of outcomes at 12-month according to Adipo-IR

From: Adipose tissue specific insulin resistance and prognosis of nondiabetic patients with ischemic stroke

    

Model 1a

 

Model 2 b

 

Model 3 c

 

Outcomes

Adipo-IR groups

N

Events, n (%)

HR/OR (95%CI)d

P Value

HR/OR (95%CI)d

PValue

HR/OR (95%CI)d

P Value

Stroke recurrence

Q1 (< 2.28)

447

24 (5.4)

Ref.

 

Ref.

 

Ref.

 
 

Q2 (2.28-4.00)

440

39 (8.9)

1.84 (1.08–3.13)

0.03

1.77 (1.04–3.03)

0.04

1.68 (1.24–2.28)

< 0.001

 

Q3 (4.01–6.05)

447

48 (10.7)

2.32 (1.38–3.90)

0.002

2.19 (1.30–3.68)

0.003

2.08 (1.55–2.80)

< 0.001

 

Q4 (6.06–9.49)

441

37 (8.4)

1.93 (1.11–3.36)

0.02

1.84 (1.06–3.21)

0.03

1.82 (1.33–2.50)

< 0.001

 

Q5 (≥ 9.50)

447

37 (8.3)

2.22 (1.27–3.91)

0.01

2.11 (1.20–3.71)

0.01

2.12 (1.55–2.91)

< 0.001

 

Per SD

  

1.19 (1.02–1.39)

0.03

1.19 (1.01–1.39)

0.03

1.22 (1.12–1.33)

< 0.001

 

P for trend

   

0.04

 

0.055

 

< 0.001

Combined vascular eventse

Q1 (< 2.28)

447

28 (6.3)

Ref.

 

Ref.

 

Ref.

 
 

Q2 (2.28-4.00)

440

41 (9.3)

1.65 (0.99–2.72)

0.052

1.60 (0.97–2.64)

0.07

1.51 (1.13–2.01)

0.01

 

Q3 (4.01–6.05)

447

49 (11.0)

2.02 (1.24–3.30)

0.01

1.91 (1.17–3.13)

0.01

1.82 (1.38–2.40)

< 0.001

 

Q4 (6.06–9.49)

441

38 (8.6)

1.69 (0.99–2.86)

0.051

1.62 (0.96–2.75)

0.07

1.61 (1.20–2.17)

0.002

 

Q5 (≥ 9.50)

447

37 (8.3)

1.91 (1.11–3.26)

0.02

1.80 (1.05–3.09)

0.03

1.81 (1.34–2.45)

< 0.001

 

Per SD

  

1.17 (1.02–1.37)

0.045

1.17 (0.98–1.37)

0.055

1.20 (1.10–1.31)

< 0.001

 

P for trend

   

0.08

 

0.12

 

0.003

Death

Q1 (< 2.28)

447

12 (2.7)

Ref.

 

Ref.

 

Ref.

 
 

Q2 (2.28-4.00)

440

9 (2.0)

0.92 (0.37–2.29)

0.86

0.91 (0.36–2.32)

0.84

0.91 (0.54–1.54)

0.72

 

Q3 (4.01–6.05)

447

16 (3.6)

1.55 (0.68–3.52)

0.30

1.72 (0.75–3.99)

0.20

1.68 (1.04–2.71)

0.03

 

Q4 (6.06–9.49)

441

9 (2.0)

1.07 (0.41–2.84)

0.89

1.16 (0.43–3.14)

0.76

1.23 (0.71–2.14)

0.47

 

Q5 (≥ 9.50)

447

12 (2.7)

1.77 (0.72–4.36)

0.21

1.55 (0.62–3.91)

0.35

1.53 (0.91–2.57)

0.11

 

Per SD

  

1.07 (0.78–1.46)

0.67

1.01 (0.74–1.38)

0.95

0.99 (0.84–1.18)

0.95

 

P for trend

   

0.19

 

0.33

 

0.08

Poor outcomef

Q1 (< 2.28)

439

43 (9.8)

Ref.

 

Ref.

 

Ref.

 
 

Q2 (2.28-4.00)

427

47 (11.0)

1.20 (0.76–1.91)

0.44

1.19 (0.73–1.95)

0.49

1.19 (0.90–1.58)

0.21

 

Q3 (4.01–6.05)

436

52 (11.9)

1.45 (0.92–2.28)

0.11

1.35 (0.83–2.19)

0.22

1.30 (0.99–1.71)

0.06

 

Q4 (6.06–9.49)

435

53 (12.2)

1.72 (1.07–2.75)

0.02

1.62 (0.98–2.69)

0.06

1.62 (1.22–2.15)

0.001

 

Q5 (≥ 9.50)

432

55 (12.7)

2.00 (1.23–3.24)

< 0.001

1.53 (0.91–2.56)

0.11

1.47 (1.10–1.96)

0.01

 

Per SD

  

1.25 (1.08–1.45)

< 0.001

1.15 (0.98–1.36)

0.09

1.14 (1.04–1.25)

0.004

 

P for trend

   

0.003

 

0.09

 

<0.001

  1. Abbreviations: Adipo-IR, adipose tissue specific insulin resistance index; CI, confidence interval; HR, hazard ratio; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale score; OR, odds ratio; TOAST, Trial of Org 10,172 in Acute Stroke Treatment
  2. a Model 1: adjusted for sex and age, body mass index, hypertension, dyslipidemia, current smoking, history of antihypertensive medications, triglyceride, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol at admission, antihypertensive agents and intravenous alteplase use during hospitalization and antihypertensive agents during 1-year follow-up
  3. b Model 2: adjusted for model 1 + prior stroke, TOAST etiology subtype, pre-stroke mRS, NIHSS at admission
  4. c Model 3: model 2 using the inverse-probability-of-treatment-weighted approach to account for missing data for serum fasting insulin and fasting free fatty acids
  5. d HR for stroke recurrence, combined vascular events and death, while OR for poor outcome
  6. e Combined vascular events were defined as a composite of myocardial infarction, recurrent stroke (either ischemic or hemorrhagic) and vascular death, whichever occurred first
  7. f Poor outcome: modified Rankin Scale 3–6
Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us